Author Interview: Professor Matthew Brown, 2026
From The IMID Forum by The Immune-Mediated Inflammatory Disease Forum
February 3, 2026 · 18 min
About this episode
Professor Peter Nash interviews Professor Matthew Brown about his research on uveitis rates in axial spondyloarthritis patients treated with bimekizumab.
Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Matthew Brown, the Chief Scientific Officer at Genomics England, as they discuss his recent paper ‘Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: Pooled results from Phase 2b/3 trials’.
People in this episode
Host: Professor Peter Nash
Guest: Professor Matthew Brown
Topics covered
- uveitis
- axial spondyloarthritis
- bimekizumab
- clinical trials
- genomics
- inflammatory diseases
Keywords
- uveitis
- axial spondyloarthritis
- bimekizumab
- clinical trials
- Professor Matthew Brown
- Professor Peter Nash
- Genomics England
Mentioned in this episode
Organizations: Genomics England
Books & works: Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: Pooled results from Phase 2b/3 trials
Places: Griffith University, Brisbane
More episodes of The IMID Forum
- EULAR 2026 Review Podcast · June 12, 2026 · 40 min
- EULAR 2026 Day 4 Highlights Podcast · June 6, 2026 · 5 min
- EULAR 2026 Day 3 Highlights Podcast · June 5, 2026 · 3 min
- EULAR 2026 Day 2 Highlights Podcast · June 4, 2026 · 6 min
- EULAR 2025 Day 1 Highlights Podcast · June 3, 2026 · 6 min
- Discussing RA: Comparative outcomes with upadacitinib in RA · May 28, 2026 · 9 min
Explore listener stats, chart rankings, contacts and more on the The IMID Forum podcast page.